BioSpace News Archive

Cultivarium and ATCC have entered a multi-phase research collaboration to expand the use of non-model microorganisms.

ProQR Therapeutics NV. announced the Annual General Meeting of Shareholders will take place on Wednesday, May 17, 2023 at 16:00 CET at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands.

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today presented promising clinical data from its Phase 1/2a first-in-human study of its DNA-based personalized cancer immunotherapy, EVX-02 in combination with the checkpoint inhibitor nivolumab.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, and Intermountain Precision Genomics, a service of Intermountain Health, are now certified to offer solid tumor testing to patients in all 50 U.S. states after receiving the New York State Clinical Laboratory Permit.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, May 2, 2023 to report its first quarter 2023 financial results and provide a corporate update.

Nuvectis Pharma, Inc. today provided highlights from the poster presentation of NXP800 that took place yesterday at the American Association for Cancer Research (“AACR”) Annual Meeting 2023 in Orlando, FL (to view the poster, titled Inhibition of HSF1 Demonstrates Therapeutic Efficacy in Preclinical PDX Models of Human Cholangiocarcinoma.

Humacyte, Inc. (Nasdaq: HUMA) announced the publication of a preclinical study in the Journal of Trauma and Acute Care Surgery comparing the use of its Human Acellular Vessel (HAV) to expanded polytetrafluorethylene (ePTFE) grafts for vascular repair following arterial trauma. In the preclinical study the HAV performed better than ePTFE on multiple indices.

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it will report operating and financial results for the first quarter ended March 31, 2023 after the market close on Tuesday, May 2, 2023.

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, attended the 2023 Emerging Topic Conference on NASH Cirrhosis: From Mechanisms to Management, sponsored by the American Association for the Study of Liver Diseases (AASLD)

Science 37 Holdings, Inc., the industry-leading Metasite™, announced the appointment of Irena Lambridis as its Global Head of Quality Assurance & Compliance.